Allgens Medical Technology CO., LTD. (SHA:688613)
China · Delayed Price · Currency is CNY 23.48
-0.44 (-1.84%)
At close: Feb 13, 2026
SHA:688613 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 208.18 | 200.43 | 218.43 | 240.28 | 234.15 | 183.76 |
Other Revenue | 5.6 | 5.6 | 8.05 | 5.02 | 1.91 | - |
| 213.78 | 206.03 | 226.48 | 245.31 | 236.06 | 183.76 | |
Revenue Growth (YoY) | 11.82% | -9.03% | -7.68% | 3.91% | 28.46% | 9.00% |
Cost of Revenue | 70.06 | 59.4 | 39.24 | 40.79 | 35.62 | 29.96 |
Gross Profit | 143.72 | 146.63 | 187.24 | 204.51 | 200.44 | 153.8 |
Selling, General & Admin | 113.06 | 123.6 | 122.04 | 69.95 | 53.35 | 39.73 |
Research & Development | 41.85 | 38.77 | 45.5 | 57.46 | 33.23 | 16.01 |
Other Operating Expenses | 5.05 | 3.57 | 2.58 | 2.58 | 3.09 | 2.42 |
Operating Expenses | 162.25 | 174.08 | 171.22 | 130.6 | 90.16 | 58.05 |
Operating Income | -18.52 | -27.44 | 16.02 | 73.91 | 110.28 | 95.75 |
Interest Expense | -2.52 | -2.95 | -3.13 | -1.87 | -3.42 | -1.28 |
Interest & Investment Income | 1.5 | 15.06 | 6.18 | 5.62 | 4.28 | 0.13 |
Earnings From Equity Investments | - | - | - | - | 0.53 | 2.03 |
Currency Exchange Gain (Loss) | -0.13 | -0.13 | 0 | 0 | -0 | -0.38 |
Other Non Operating Income (Expenses) | -2.31 | -1.13 | -0.34 | 0.05 | -0.07 | -0.03 |
EBT Excluding Unusual Items | -21.99 | -16.59 | 18.73 | 77.72 | 111.61 | 96.22 |
Gain (Loss) on Sale of Investments | 13.68 | 6.35 | 15.1 | 10.2 | 14.39 | 2.5 |
Gain (Loss) on Sale of Assets | 0.15 | 0.64 | -0.59 | -0.32 | - | -0.08 |
Asset Writedown | - | - | - | - | -0.01 | - |
Other Unusual Items | 3.54 | 0.66 | 15.85 | 8.61 | 6.07 | 3.43 |
Pretax Income | -4.62 | -8.94 | 49.09 | 96.2 | 132.05 | 102.08 |
Income Tax Expense | 1.11 | 8.2 | -3.87 | 4.5 | 13.98 | 14.96 |
Earnings From Continuing Operations | -5.73 | -17.14 | 52.97 | 91.7 | 118.07 | 87.12 |
Minority Interest in Earnings | 2.12 | 4.48 | 1.27 | 3.52 | 2.71 | 1.83 |
Net Income | -3.61 | -12.66 | 54.23 | 95.22 | 120.78 | 88.94 |
Net Income to Common | -3.61 | -12.66 | 54.23 | 95.22 | 120.78 | 88.94 |
Net Income Growth | - | - | -43.04% | -21.17% | 35.80% | 31.22% |
Shares Outstanding (Basic) | 154 | 141 | 132 | 134 | 120 | 100 |
Shares Outstanding (Diluted) | 154 | 141 | 132 | 134 | 120 | 100 |
Shares Change (YoY) | 22.74% | 6.36% | -1.37% | 12.14% | 19.66% | -0.06% |
EPS (Basic) | -0.02 | -0.09 | 0.41 | 0.71 | 1.01 | 0.89 |
EPS (Diluted) | -0.02 | -0.09 | 0.41 | 0.71 | 1.01 | 0.89 |
EPS Growth | - | - | -42.25% | -29.70% | 13.48% | 31.30% |
Free Cash Flow | -24.26 | -33.03 | 29.78 | 56.63 | 68.54 | 28.47 |
Free Cash Flow Per Share | -0.16 | -0.23 | 0.23 | 0.42 | 0.57 | 0.28 |
Dividend Per Share | - | - | 0.060 | 0.107 | 0.272 | - |
Dividend Growth | - | - | -43.92% | -60.66% | - | - |
Gross Margin | 67.23% | 71.17% | 82.67% | 83.37% | 84.91% | 83.70% |
Operating Margin | -8.67% | -13.32% | 7.07% | 30.13% | 46.72% | 52.11% |
Profit Margin | -1.69% | -6.15% | 23.95% | 38.82% | 51.17% | 48.40% |
Free Cash Flow Margin | -11.35% | -16.03% | 13.15% | 23.09% | 29.04% | 15.50% |
EBITDA | 0.16 | -10.43 | 30.81 | 88.11 | 121.03 | 107.06 |
EBITDA Margin | 0.08% | -5.06% | 13.61% | 35.92% | 51.27% | 58.26% |
D&A For EBITDA | 18.69 | 17.02 | 14.79 | 14.2 | 10.75 | 11.31 |
EBIT | -18.52 | -27.44 | 16.02 | 73.91 | 110.28 | 95.75 |
EBIT Margin | -8.67% | -13.32% | 7.07% | 30.13% | 46.72% | 52.11% |
Effective Tax Rate | - | - | - | 4.68% | 10.59% | 14.66% |
Revenue as Reported | 213.78 | 206.03 | 226.48 | 245.31 | 236.06 | 183.76 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.